Securities code: Boya Bio-Pharmaceutical Group Co.Ltd(300294) securities abbreviation: Boya Bio-Pharmaceutical Group Co.Ltd(300294) Announcement No.: 2022014 Boya Bio-Pharmaceutical Group Co.Ltd(300294)
Announcement on 2021 profit distribution plan
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete without false records, misleading statements or major omissions.
1、 Basic information of profit distribution plan
1. Proposer of the specific content of the profit distribution plan: Boya Bio-Pharmaceutical Group Co.Ltd(300294) the board of directors proposed reason: in view of the company’s good operation and broad development prospects in the future, in order to repay all shareholders and share the company’s operating results with all shareholders, this plan is proposed for the company’s profit distribution plan for 2021 on the premise of conforming to the profit distribution principle and ensuring the normal operation and long-term development of the company.
Bonus shares (shares) dividend (yuan) conversion of accumulation fund into share capital (shares)
0 1.5 0 for every ten shares
The company’s profit distribution plan for 2021 is as follows: taking 504248738 shares as the base (the total distribution of the company’s total shares is 511633438 shares, deducting the number of special accounts for repurchase of the company), distribute cash dividends of 1.5 yuan (including tax) to all shareholders for every 10 shares, give bonus shares of 0 shares (including tax), and transfer capital reserve to all shareholders for every 10 shares.
According to the detailed rules for the implementation of share repurchase by listed companies of Shenzhen Stock Exchange: the amount of share repurchase prompted for implementation in that year is regarded as the amount of cash dividend, which is included in the relevant proportion of cash dividend in that year. In 2021, the company did not repurchase shares.
2. Legality and compliance of profit distribution plan
The company’s profit distribution plan for 2021 complies with the provisions of the company law, the notice on further implementing matters related to cash dividends of listed companies, the guidelines for the supervision of listed companies No. 3 – cash dividends of listed companies and the articles of association, as well as the profit distribution policy, profit distribution plan and relevant commitments in the company’s shareholder dividend return plan (20212023).
3. Matching of profit distribution plan with the company’s growth
During the reporting period, focusing on the development strategy, the board of directors and management of the company strengthened fine management, refined business objectives, ensured the orderly development of various production and business activities, laid the foundation for the sustainable development of the company, and well completed the annual business indicators through the efforts of all employees.
Blood products belong to the subdivided industry of biological products. Since the state has not approved new blood products enterprises since 2001, the blood products enterprise license has become a scarce resource. The state has highly supervised the blood products industry and continuously raised the entry threshold of the industry. In addition, the demand for blood products is growing rapidly, and the blood products industry maintains a high prosperity, which makes the supply and demand of blood products increasingly tense. Meanwhile, in recent years, the China Meheco Group Co.Ltd(600056) industry has been in a sustained, stable and rapid development stage. Economic development and medical system reform have promoted the continuous release of demand, and the consumption of China Meheco Group Co.Ltd(600056) industry has maintained a high-speed growth. The future will be a critical period for the development of the pharmaceutical industry. With the introduction of policies on biopharmaceutical, accelerating medical reform and structural adjustment of the pharmaceutical industry, the pharmaceutical industry will usher in a new round of development opportunities. Benefiting from the good development trend of the pharmaceutical industry, the company will develop steadily and healthily to achieve its strategic objectives. The company invested in the construction of “blood products intelligent factory (phase I) construction project” in combination with the actual situation to match the company’s strategic development.
The company’s profit distribution plan for 2021 is: Based on 504248738 shares (511633438 shares of the company’s total share capital minus the number of special accounts for repurchase of the company), distribute cash dividends of 1.5 yuan (including tax) to all shareholders for every 10 shares, give bonus shares of 0 shares (including tax), and transfer capital reserve to all shareholders for every 10 shares. The total cash dividend accounts for 21.95% of the net profit attributable to the shareholders of the listed company.
The company’s profit distribution plan for 2021 matches the company’s performance growth.
2、 Relevant risk tips
The company’s profit distribution plan for 2021 has been deliberated and approved at the 15th meeting of the 7th board of directors and the 12th meeting of the 7th board of supervisors of the company, and needs to be deliberated by the general meeting of shareholders of the company.
3、 Other instructions
Before the disclosure of this profit distribution plan, the company strictly controlled the scope of insiders, performed the obligation of confidentiality and prohibition of insider trading for insiders who knew the matter, and filed and registered.
4、 Documents for future reference
1. Resolutions of the 15th meeting of the 7th board of directors of the company;
2. Resolutions of the 12th meeting of the 7th board of supervisors of the company;
3. Opinions of independent directors.
It is hereby announced.
Boya Bio-Pharmaceutical Group Co.Ltd(300294) board of directors March 22, 2022
